As the healthcare data landscape continues to evolve and transform, the ability to discover and evaluate real-world data (RWD) with speed and precision is a critical advantage. For life sciences organizations conducting clinical research, health economics and outcomes research (HEOR), and post-marketing surveillance, faster access to fit-for-purpose data can directly translate into reduced costs, shorter timelines, and ultimately, better patient outcomes.

That’s why Veradigm, a leading healthcare technology company, is among the first data providers to adopt Datavant Connect powered by AWS Clean Rooms, a groundbreaking cloud-first solution designed to modernize the way real-world data is assessed, accessed, and activated.

Veradigm recognized early the opportunity to join Datavant in this next wave of innovation, leveraging secure, live data connections to streamline RWD discovery for life sciences researchers.

“Making our Clinical Data Registries available on the Datavant Connect platform is a pivotal step in advancing real-world evidence generation,” said Stuart Green, SVP and GM of Veradigm Life Science. “Life Sciences organizations can now access and evaluate our robust cardiometabolic datasets faster and more efficiently – helping accelerate research, reduce costs, and bring innovative therapies to the patients who need them most.”

A Smarter, Faster Path to the Right Data

Powered by AWS Clean Rooms, Datavant Connect enables data consumers to evaluate datasets from multiple providers simultaneously—without requiring any underlying data movement. Data sources register their datasets in the platform via a live connection to their AWS S3 environment. This eliminates the need for manual data refreshes, reduces technical overhead, and ensures data consumers are always working with the most up-to-date information.

For researchers, this means the ability to perform feasibility queries, run pre-set reports, and test hypotheses across a broader and deeper range of data assets—all before making a data purchase. For data partners like Veradigm, it enables greater visibility and data discoverability, while maintaining full control of proprietary data.

Why Veradigm’s Data Stands Out

Veradigm’s early adoption is particularly noteworthy given the unique strength of its real-world data assets. The company operates clinical data registries in collaboration with the American College of Cardiology, drawing from a diverse network of providers across more than 80 electronic health record (EHR) systems. These registries offer rich, structured, and unstructured data—augmented by Veradigm’s advanced natural language processing (NLP) capabilities—to support robust cardiometabolic research.

Life sciences companies seeking data to support phase IV studies, epidemiology, HEOR, and risk management in cardiovascular and metabolic conditions will find Veradigm’s data particularly valuable. The availability of this data through Datavant Connect not only broadens access, but also empowers researchers to validate its utility before purchase.

Driving Value Across the Healthcare Ecosystem

Veradigm’s involvement reflects a broader transformation in the way data providers and data consumers interact. Traditionally, evaluating RWD has been a manual, time-consuming process that often involves multiple rounds of sample data, NDAs, and custom extracts. Datavant Connect removes those barriers—establishing a new standard for how data partnerships form and scale.

By becoming an early adopter, Veradigm is not only gaining visibility with new customers but also unlocking valuable insights into what those customers are searching for. With access to feasibility queries and search trends, Veradigm can better understand demand patterns and tailor its offerings accordingly.

Designed for Life Sciences

While Datavant Connect benefits a wide range of healthcare stakeholders, its impact on life sciences research is especially significant. The platform was built to address the specific needs of clinical and commercial teams seeking fit-for-purpose data to inform studies, regulatory filings, and commercialization strategies.

For Veradigm, this aligns perfectly with its strategic focus. The company serves a range of life sciences personas—from RWE and HEOR teams to clinical trial sponsors and commercial analytics groups—who need access to comprehensive EHR data on cardiovascular and metabolic patients.

The ability to explore Veradigm’s datasets in a cloud-native environment helps life sciences teams reduce costs, mitigate risk, and accelerate research timelines. It also supports more equitable data access, enabling small to mid-size pharma and biotech firms to evaluate high-value datasets without the technical barriers that traditionally limit participation.

Looking Ahead: A New Standard for RWD Discovery

Veradigm’s adoption of Datavant Connect powered by AWS Clean Rooms represents more than just a technology implementation—it signals a strategic shift toward greater transparency, speed, and collaboration in the healthcare data ecosystem.

By embracing a cloud-first approach, Veradigm is reducing the time and effort it takes for life sciences teams to discover and evaluate real-world data. At the same time, it’s gaining new insights into customer needs, improving its data offerings, and building more enduring partnerships.

As more data sources join the movement, the value of cloud-first data discovery and assessment will continue to grow—enabling even more powerful, privacy-preserving collaborations across the industry.

Learn more about Veradigm’s Clinical Data Registries here.